Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01059526 · ClinicalTrials.gov registry record
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
A clinical trial, sponsored by Shire.
- Completed
- Registry status
- 81
- Enrollment target
NCT01059526 is a clinical trial that has completed, run by Shire. The registered enrollment target is 81 participants.
The verdict
NCT01059526 has completed, sponsored by Shire.
- COMPLETED
- Registry status
- 81 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the formation of antibodies, the occurence of allergic reactions, and the risk of hypercoagulability and hypocoagulability in patients treated with KALBITOR (ecallantide).
Interventions
- DRUG ecallantide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2010-02-01 |
| Est. Completion | 2014-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01059526
The ClinicalTrials.gov registry entry for NCT01059526 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ecallantide is the first listed.
NCT01059526 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01059526 about?
NCT01059526 is a clinical study titled "Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema". The objective of this study is to evaluate the formation of antibodies, the occurence of allergic reactions, and the risk of hypercoagulability and hypocoagulability in patients treated with KALBITOR (ecallantide).
What is the current status of trial NCT01059526?
This trial is currently completed. The enrollment target is 81 participants. The study started on 2010-02-01. Estimated completion is 2014-06-01.
What interventions are being tested in trial NCT01059526?
The interventions under investigation include: ecallantide (DRUG).
Who is sponsoring clinical trial NCT01059526?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.